Bluejay (BJDX): רווח נקי למניה (EPS TTM)

Net income per share over the last four quarters demonstrates current momentum, where -38.25 records a new level. An increase in the value of Bluejay Diagnostics (BJDX) securities is expected following the receipt of FDA clearances for sepsis rapid tests. The laboratory diagnostics sector is not subject to economic cycles or seasonality. Bluejay Diagnostics (BJDX) generates revenue from the supply of Symphony systems to cardiology centers and emergency departments.

The 12-month EPS trend chart clearly reflects the implementation efficiency of Bluejay Diagnostics (BJDX) rapid diagnostic systems. This indicator is calculated as the ratio of net income to the total number of outstanding shares, determining the business's equity return. The growth of this metric confirms the monetization of the consumables model through high-margin cartridge sales. Analyzing the curve allows investors to filter out market noise and assess the real profitability of each security. The steady increase in this figure indicates high asset quality.